Building Data Quality In Generates Quality Data Out

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2020
Volume 2020 eBook
Issue 2
Pages: 4-9

Ensuring the quality of data in process monitoring and control systems starts in process development phases.

Ensuring the quality of data in process monitoring and control systems starts in process development phases. Maintaining data integrity during scale up and technical transfer phases is crucial. Building quality features into data management systems is a recommended strategy.

Read this article in Pharmaceutical Technology’s May 2020 Biologics and Sterile Drug Manufacturing eBook. 

Article Details

Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2020
May 2020
Pages: 4–9

Citation

When referring to this article, please cite it as C. Challener, “Building Data Quality In Generates Quality Data Out," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).

 

Articles in this issue
PTebook0520_PreFilled-Syringes_Main-Image.gif
On Point: Biologics Drive Growth in Pre-Filled Syringes
Screen Shot_225.jpg
Instrumenting Single-Use Processes
Ebook_Contamination Control_225.jpg
Considerations in Contamination Control
Best systems and equipment for contamination control
Ebook_Development_225.jpg
Building Data Quality In Generates Quality Data Out
PTeBook0520_ContaminationCellTherapy_main225.jpg
Detecting Contamination in Cell Therapies
PTeBook0520_SeparationViralVector_main225.jpg
Optimizing Viral Vector Manufacturing for Gene Therapy
PTEebook0520_thermo.jpg
Minimizing Contamination During Biopharma R&D
PTEebook0520_agalloco-1.jpg
Complications in Process Simulation Execution
Recent Videos
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

Feliza Mirasol
December 20th 2024
Article

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Intertek Teams Up with CrystecPharma on Formulation and Development of Dry Powder Inhaler Products

Feliza Mirasol
December 13th 2024
Article

The partners will aim to establish a platform that enables rapid development of DPI products.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novartis Enters $2.9 Billion License Agreement with PTC Therapeutics for Huntington’s Disease Development Program

Feliza Mirasol
December 10th 2024
Article

Novartis will in-license PTC's PTC518 program, which has the potential become the first oral disease-modifying therapy for Huntington's disease.

Human head shape made from a large grid of pins connected with string. Communication technology and mental health concept | Image Credit: © ink drop - Stock.adobe.com

European Biotechs Unlocking Parkinson’s Disease

Cheryl Barton
December 9th 2024
Article

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.